Brought to you by 
Janssen gets ex-Chinese rights to HBV therapies from Chia Tai
11 Jan 2016
Executive Summary
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. licensed Janssen Pharmaceuticals Inc. exclusive rights to develop and commercialize outside of China undisclosed immuno-modulating agents to treat chronic hepatitis B virus.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen gets ex-Chinese rights to HBV therapies from Chia Tai
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice